PROGRESSIVE SUPRANUCLEAR PALSY

This study looked at the long-term safety of a drug called GV1001 in people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and balance. 67 patients who had already completed a previous GV1001 trial received daily injections for another 12 mo…

This study tested whether the drug AMX0035 can slow down or improve symptoms of Progressive Supranuclear Palsy (PSP), a rare brain disease that affects movement, balance, and thinking. About 139 adults aged 40 to 80 with early-stage PSP took either the drug or a placebo for sever…

This study tested a drug called GV1001 in 78 people with Progressive Supranuclear Palsy (PSP), a rare brain disease that affects movement and thinking. Participants received daily injections of either a low dose, a high dose, or a placebo for 6 months. The goal was to see if the …

This study tested a new drug called TPN-101 in 42 people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and thinking. The main goal was to see if the drug is safe and tolerable over 48 weeks. Researchers also looked at how the drug moves in …

This study looked at how the front part of the brain helps with reasoning and categorizing things. Researchers compared healthy volunteers to people with frontotemporal dementia or progressive supranuclear palsy. They used tasks, brain scans, and magnetic stimulation to understan…